Drugs / Nivolumab
Nivolumab
Drug FDA approvedMarketed as Opdivo
PD-1 blocking antibody·First approved·2014·1 brand
- Registered trials
- 1348
- Ongoing
- 484/ 36%
- Completed
- 520
- Indications
- 11
Approved indications by brand
| Brand | Indication |
|---|---|
| Opdivo | Melanoma |
| Non-small cell lung cancer | |
| Renal cell carcinoma | |
| Hodgkin lymphoma | |
| Head and neck cancer | |
| Urothelial carcinoma | |
| Colorectal cancer | |
| Hepatocellular carcinoma | |
| Esophageal carcinoma | |
| Malignant pleural mesothelioma | |
| Gastric cancer |
Clinical trial landscape
1348 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 2 | 605 | 244 | 207 | |
| Phase 1 | 284 | 89 | 118 | |
| Phase 1/2 | 239 | 63 | 97 | |
| Phase 3 | 119 | 53 | 53 | |
| Unknown | 35 | 6 | 20 | |
| Early Phase 1 | 26 | 9 | 12 | |
| Phase 2/3 | 20 | 11 | 5 | |
| Not applicable | 11 | 6 | 3 | |
| Phase 4 | 9 | 3 | 5 | |
| All phases | 1348 | 484 | 520 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Programmed death receptor-1 (PD-1) immune checkpoint blockade.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.